Acquired Vancomycin Resistance in Clinically Relevant Pathogens
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Acquired resistance to vancomycin is an increasing problem in pathogenic bacteria. It is best studied and most prevalent among Enterococcus and still remains rare in other pathogenic bacteria. Different genotypes of vancomycin resistance, vanA-G, have been described. The different van gene clusters consist of up to nine genes encoding proteins of different functions; their interplay leads to an alternative cell wall precursor less susceptible to glycopeptide binding. Variants of vanA and vanB types are found worldwide, with vanA predominating; their reservoir is Enterococcus faecium. Within this species a subpopulation of hospital-adapted types exists that acquired van gene clusters and which is responsible for outbreaks of vancomycin-resistant enterococci all over the world. Acquisition of vanA by methicillin-resistant Staphylococcus aureus (MRSA) is worrisome and seven cases have been described. Nonsusceptibility to glycopeptides also occurs independently from van genes and is a growing therapeutic challenge, especially in MRSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984 · cited 1×
“aureus exhibiting reduced susceptibility to glycopeptides came from Japan in 1997 [92].”
BackgroundInfection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025025 · Cited by 1,095 · cited 1×
“aureus (VRSA) was isolated from a dialysis patient in Michigan, USA [78,79].”
BackgroundVancomycin Resistance in Gram-Positive Cocci
Courvalin, P. (2006) · Clinical Infectious Diseases · doi:10.1086/491711 · Cited by 1,028 · cited 7×
“A protein, VanZ, confers low-level teicoplanin resistance via an unknown mechanism [28].”
BackgroundInfluentialVancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006
Sievert, D. M., Rudrik, J. T., Patel, J. B., McDonald, L. C., Wilkins, M. J., & Hageman, J. C. (2008) · Clinical Infectious Diseases · doi:10.1086/527392 · Cited by 483
Wootton, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.399 · Cited by 414 · cited 1×
“[95] and became the ‘gold standard’ for detecting hVISA in large surveillance studies.”
BackgroundVancomycin-resistant enterococci: why are they here, and where do they come from?
Bonten, M. J., Willems, R., & Weinstein, R. A. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00145-1 · Cited by 400
Fridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., Tenover, F. C., & the Vancomycin‐Intermediate Staphylococcus aureus Epidemiology Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/346207 · Cited by 344 · cited 2×
“Initially, only VISA isolates were accepted to be responsible for vancomycin treatment failures, but increasing numbers of studies demonstrated that hVISA were also associated with treatment failure as well as with increased mortality [121–126].”
BackgroundGenes homologous to glycopeptide resistance van A are widespread in soil microbial communities
Guardabassi, L., & Agersø, Y. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00270.x · Cited by 47 · cited 2×
“There may be a reservoir of transferable van genotypes present outside enterococci [70–73], for instance, in species from human bowel flora [70,71,74].”
Background
Cited by
The rise of the Enterococcus: beyond vancomycin resistance
Arias, C. A., & Murray, B. E. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2761 · Cited by 1,776
“The mechanism of vancomycin resistance has been extensively reviewed previousl”
BackgroundAnti-virulence strategies to combat bacteria-mediated disease
Rasko, D. A., & Sperandio, V. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3013 · Cited by 1,373
Recovery of gut microbiota of healthy adults following antibiotic exposure
Palleja, A., Mikkelsen, K. H., Forslund, S. K., Kashani, A., Allin, K. H., Nielsen, T., Hansen, T. H., Liang, S., Feng, Q., Zhang, C., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0257-9 · Cited by 875
Cong, Y., Yang, S., & Rao, X. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2019.10.005 · Cited by 527
Biofilm-associated infection by enterococci
Ch’ng, J.-H., Chong, K. K. L., Lam, L. N., Wong, J. J., & Kline, K. A. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0107-z · Cited by 447
Metadata
- Authors
- Werner, G., Strommenger, B., & Witte, W.
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2008-09-23
- Volume
- 3
- Issue
- 5
- Pages
- 547-562
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W2122044739
- Cited by
- 82
- References
- 8
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acquired Vancomycin Resistance in Clinically Relevant Pathogens. https://app.cochat.ai/papers/10.2217/17460913.3.5.547
- The paper
- Werner, G., Strommenger, B., & Witte, W. (2008). Acquired Vancomycin Resistance in Clinically Relevant Pathogens. Future Microbiology. https://doi.org/10.2217/17460913.3.5.547
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.